ストックスクリーナーアプリを入手
9.29
0.43%
0.04
アフターアワーズ：
9.24
-0.05
-0.54%
前日終値:
$9.25
開ける：
$9.34
24時間の取引高:
816.34K
Relative Volume:
0.57
時価総額：
$824.61M
収益：
$67.48M
当期純損益:
$-278.67M
株価収益率:
-2.9238
EPS:
-3.1774
ネットキャッシュフロー:
$-70.70M
1週間 パフォーマンス:
+5.21%
1か月 パフォーマンス:
+7.90%
6か月 パフォーマンス:
-6.54%
1年 パフォーマンス:
+38.24%
1日の値動き範囲:
$9.035
$9.415
1週間の範囲:
$8.53
$9.42
52週間の値動き範囲:
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
名前
Kura Oncology Inc
セクター
電話
(858) 500-8800
住所
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.29 | 821.06M | 67.48M | -278.67M | -70.70M | -3.1774 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | 開始されました | Lake Street | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Neutral |
| 2025-02-06 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-14 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-08-11 | 開始されました | BofA Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Perform |
| 2023-05-17 | 開始されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2022-07-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 開始されました | Jefferies | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2020-12-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-11-05 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 開始されました | Credit Suisse | Outperform |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2018-11-09 | 開始されました | Piper Jaffray | Overweight |
| 2018-08-01 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-13 | 再開されました | Leerink Partners | Outperform |
| 2016-01-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-12-30 | 開始されました | Oppenheimer | Outperform |
| 2015-12-16 | 開始されました | Citigroup | Buy |
すべてを表示
Kura Oncology Inc (KURA) 最新ニュース
Kura Oncology schedules May 12 webcast for Q1 2026 results - Stock Titan
Kura Oncology to Report First Quarter 2026 Financial Results - Yahoo Finance
How The Kura Oncology (KURA) Story Is Evolving After Komzifti Launch And Q4 Reassessment - Yahoo Finance
Five new Kura hires get stock options for 133,750 shares - Stock Titan
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
KURA Stock Price, Quote & Chart | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Vanguard reports 5.01% stake in Kura Oncology (NASDAQ: KURA) - Stock Titan
Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Kura Oncology (KURA) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Moody Aldrich Partners LLC Buys New Position in Kura Oncology, Inc. $KURA - MarketBeat
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML - marketscreener.com
Kyowa Kirin Co., Ltd. And Kura Oncology, Inc. Advance Ziftomenib With Japan Phase 2 Trial In NPM1 Mutated AML - BioPharma APAC
Kura rises after early-stage trial data for kidney cancer therapy - MSN
Kura Oncology shares jump on encouraging kidney cancer trial results - MSN
KURA Financials: Income Statement, Balance Sheet & Cash Flow | Kura Oncology Inc - Stock Titan
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2025 earnings call transcript - MSN
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell CarcinomaSlideshow (NASDAQ:KURA) 2026-04-21 - Seeking Alpha
Barclays Sticks to Their Buy Rating for Kura Oncology (KURA) - The Globe and Mail
Kura Oncology: Poised For A Lift With Combinations (NASDAQ:KURA) - Seeking Alpha
Is Kura Oncology (KURA) stock expanding in volatility (+1.45%) 2026-04-20Community Sell Signals - Cổng thông tin điện tử tỉnh Tây Ninh
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data - TradingView
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last? - Yahoo Finance
Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How The Kura Oncology (KURA) Narrative Is Shifting With Komzifti Launch And New Analyst Targets - Yahoo Finance
Kura Oncology Advances Kidney Cancer Program With Solid Early-Stage Results - Sahm
KURA: Promising Results from Kura Oncology's Trial on ccRCC Trea - GuruFocus
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Kura Oncology (NASDAQ:KURA) Stock Price Up 9.7%Time to Buy? - MarketBeat
Kura Oncology (KURA) Shows Promising Phase 1 Trial Results for K - GuruFocus
Kura Oncology shares jump on positive kidney cancer trial data By Investing.com - Investing.com Canada
Kura Oncology Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib - The Manila Times
Kura Oncology Announces Promising Preliminary Data on Darlifarnib in Combination with Cabozantinib for ccRCC Patients Previously Treated with Cabozantinib - Quiver Quantitative
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients ... - Enidnews.com
Kura Oncology Reports Darlifarnib Plus Cabozantinib - GlobeNewswire
Kura Oncology, Inc. (KURA) Stock Analysis: A 247% Upside Potential Beckons Investors - DirectorsTalk Interviews
Kura Oncology shares jump on positive kidney cancer trial data - Investing.com
Kura Oncology (NASDAQ:KURA) Raised to Strong-Buy at Lake Street Capital - MarketBeat
Lake Street initiates coverage of Kura Oncology (KURA) with buy recommendation - MSN
Kura Oncology Inc (KURA) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):